ING Groep NV decreased its position in Shire PLC (NASDAQ:SHPG) by 48.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,737 shares of the biopharmaceutical company’s stock after selling 5,492 shares during the period. ING Groep NV’s holdings in Shire were worth $879,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Hartford Financial Management Inc. lifted its holdings in shares of Shire by 5.4% in the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 32 shares during the last quarter. YorkBridge Wealth Partners LLC lifted its holdings in shares of Shire by 81.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 317 shares during the last quarter. Pacer Advisors Inc. acquired a new position in shares of Shire in the 2nd quarter worth approximately $171,000. Stephens Inc. AR lifted its holdings in shares of Shire by 22.2% in the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 228 shares during the last quarter. Finally, Ingalls & Snyder LLC lifted its holdings in shares of Shire by 10.8% in the 2nd quarter. Ingalls & Snyder LLC now owns 1,284 shares of the biopharmaceutical company’s stock worth $212,000 after acquiring an additional 125 shares during the last quarter. 18.64% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have recently commented on SHPG shares. ValuEngine lowered shares of Shire from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research upgraded shares of Shire from a “sell” rating to a “hold” rating in a report on Friday, October 27th. Cantor Fitzgerald restated a “buy” rating and issued a $222.00 price objective on shares of Shire in a report on Friday, October 27th. Liberum Capital upgraded shares of Shire from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. Finally, BidaskClub lowered shares of Shire from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $212.18.

Shares of Shire PLC (SHPG) opened at $147.86 on Monday. The stock has a market cap of $44,870.00, a P/E ratio of 10.17, a price-to-earnings-growth ratio of 0.82 and a beta of 1.60. Shire PLC has a fifty-two week low of $137.17 and a fifty-two week high of $192.15. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55.

Shire (NASDAQ:SHPG) last announced its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.64 by $0.17. Shire had a net margin of 10.95% and a return on equity of 14.41%. The business had revenue of $3.70 billion for the quarter. During the same quarter in the previous year, the business posted $3.17 earnings per share. Shire’s revenue for the quarter was up 7.1% compared to the same quarter last year. equities analysts predict that Shire PLC will post 15 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “ING Groep NV Has $879,000 Stake in Shire PLC (SHPG)” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://theolympiareport.com/2017/11/27/ing-groep-nv-has-879000-stake-in-shire-plc-shpg.html.

Shire Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.